Continued advancements in CRISPR-Cas systems have accelerated genome research. Use of CRISPR-Cas in cancer research has been of great interest that is resulting in development of orthogonal methods for drug target validations and discovery of new therapeutic targets through genome-wide screens of cancer cells. CRISPR-based screens have also revealed several new cancer drivers through alterations in tumor suppressor genes (TSGs) and oncogenes inducing resistance to targeted therapies via activation of alternate signaling pathways. Given such dynamic status of cancer, we review the application of CRISPR-Cas in non-small cell lung cancer (NSCLC) for development of mutant models, drug screening, target validation, novel target discoveries, and other emerging potential applications. In addition, CRISPR-based approach for development of novel anticancer combination therapies is also discussed in this review.

CRISPR-Cas 系统的持续进步加速了基因组研究。在癌症研究中使用 CRISPR-Cas 引起了极大的兴趣，这导致了开发用于药物靶点验证的正交方法和通过癌细胞的全基因组筛选发现新的治疗靶点。基于 CRISPR 的筛选还通过改变肿瘤抑制基因 (TSG) 和致癌基因通过激活替代信号通路诱导对靶向治疗的抗性，揭示了几种新的癌症驱动因素。鉴于癌症的这种动态状态，我们回顾了 CRISPR-Cas 在非小细胞肺癌 (NSCLC) 中的应用，以开发突变模型、药物筛选、靶点验证、新靶点发现和其他新兴的潜在应用。此外，